ATE485055T1 - Adjuvierte antigene meningokokkenzusammensetzungen - Google Patents

Adjuvierte antigene meningokokkenzusammensetzungen

Info

Publication number
ATE485055T1
ATE485055T1 AT02788442T AT02788442T ATE485055T1 AT E485055 T1 ATE485055 T1 AT E485055T1 AT 02788442 T AT02788442 T AT 02788442T AT 02788442 T AT02788442 T AT 02788442T AT E485055 T1 ATE485055 T1 AT E485055T1
Authority
AT
Austria
Prior art keywords
adjuved
antigen
meningococcal
compositions
meningococcal compositions
Prior art date
Application number
AT02788442T
Other languages
German (de)
English (en)
Inventor
Mariagrazia Pizza
Marzia Giuliani
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE485055T1 publication Critical patent/ATE485055T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02788442T 2001-12-04 2002-12-04 Adjuvierte antigene meningokokkenzusammensetzungen ATE485055T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0129007.1A GB0129007D0 (en) 2001-12-04 2001-12-04 Adjuvanted antigenic meningococcal compositions
PCT/IB2002/005662 WO2003047619A2 (en) 2001-12-04 2002-12-04 Adjuvanted antigenic meningococcal compositions

Publications (1)

Publication Number Publication Date
ATE485055T1 true ATE485055T1 (de) 2010-11-15

Family

ID=9926977

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02788442T ATE485055T1 (de) 2001-12-04 2002-12-04 Adjuvierte antigene meningokokkenzusammensetzungen

Country Status (11)

Country Link
US (2) US20060008476A1 (https=)
EP (1) EP1448230B1 (https=)
JP (2) JP4414226B2 (https=)
AP (1) AP2004003074A0 (https=)
AT (1) ATE485055T1 (https=)
AU (1) AU2002353417A1 (https=)
CA (1) CA2468935C (https=)
CY (1) CY1111114T1 (https=)
DE (1) DE60238075D1 (https=)
GB (1) GB0129007D0 (https=)
WO (1) WO2003047619A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
ES2281409T3 (es) * 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.
KR100898648B1 (ko) * 2001-06-07 2009-05-22 와이어쓰 홀딩스 코포레이션 보조제로서 콜레라 홀로톡신의 돌연변이체 형태
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
NZ536859A (en) * 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
CN103357002A (zh) 2003-10-02 2013-10-23 诺华疫苗和诊断有限公司 多种脑膜炎球菌血清群的液体疫苗
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
HUE049695T2 (hu) 2009-03-24 2020-10-28 Glaxosmithkline Biologicals Sa Adjuváló H meningococcus faktort kötõ fehérje
KR101594228B1 (ko) 2010-08-23 2016-02-15 와이어쓰 엘엘씨 네이세리아 메닌기티디스 ｒＬＰ２０８６ 항원의 안정한 제제
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
WO2012059593A1 (en) * 2010-11-05 2012-05-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vaccines for preventing meningococcal infections
GB201102090D0 (en) * 2011-02-08 2011-03-23 Univ Sheffield Antigenic polypeptide
MX359256B (es) 2012-03-09 2018-09-19 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
AU2013295242C1 (en) 2012-07-27 2018-08-09 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2019410099A1 (en) * 2018-12-21 2021-07-15 Griffith University Compositions, methods and uses for eliciting an immune response
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US20220348645A1 (en) * 2019-10-01 2022-11-03 Beth Israel Deaconess Medical Center, Inc. Conformation-specific antibodies that bind nuclear factor kappa-light-chain-enhancer of activated b cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CN1263854C (zh) * 1997-11-06 2006-07-12 启龙股份公司 奈瑟球菌抗原
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
AU1979599A (en) * 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
ATE378066T1 (de) * 1998-09-30 2007-11-15 Wyeth Corp Mutiertes cholera holotoxin als hilfsmittel
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.

Also Published As

Publication number Publication date
EP1448230A2 (en) 2004-08-25
GB0129007D0 (en) 2002-01-23
DE60238075D1 (de) 2010-12-02
US20100233205A1 (en) 2010-09-16
CA2468935C (en) 2013-02-05
WO2003047619A2 (en) 2003-06-12
JP4414226B2 (ja) 2010-02-10
EP1448230B1 (en) 2010-10-20
AU2002353417A1 (en) 2003-06-17
JP2005511662A (ja) 2005-04-28
CY1111114T1 (el) 2015-06-11
AP2004003074A0 (en) 2004-06-30
JP2009155344A (ja) 2009-07-16
US20060008476A1 (en) 2006-01-12
CA2468935A1 (en) 2003-06-12
WO2003047619A3 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
ATE485055T1 (de) Adjuvierte antigene meningokokkenzusammensetzungen
ATE553775T1 (de) Impstoffzusammesetzung
FI20010780A0 (fi) Parannetut koostumukset
NO20026175L (no) Vaksinesammensetning
PL368370A1 (pl) Kompozycja glifosatu
ATE303787T1 (de) Schergelzusammensetzungen
IS6915A (is) Lyfjablanda
IS7297A (is) Streptococcis Pneumoniae bóluefni
DK1427444T3 (da) West-nil-vaccine
BR0210619A (pt) composição
IS7081A (is) Lyfjablanda
NO20033882D0 (no) Vaksine
DE60205322D1 (de) Fluoroelastomere
ATE314049T1 (de) Schweisshemmende zusammensetzungen
EE200300569A (et) CD44v6-spetsiifilised antikehad
DE60229463D1 (de) Fluoroelastomere
EE200300480A (et) Pregabaliini-laktoosi konjugaadid
EP1420818A4 (en) ANTIGENIC COMPOSITIONS
DE50206933D1 (de) Zweimassenschwungrad
EP1454914A4 (en) TUMOR ANTIGEN
DE60213119D1 (de) Zweimassenschwungrad
ITTO20020747A0 (it) Composizione
DE50100362D1 (de) Kreuzscheibenkupplung
DE60217632D1 (de) Wandnachbildungen
ITTO20020745A0 (it) Composizione

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties